Bayer Healthcare Shares Latest Analyses of Vitrakvi for Patients with TRK Fusion Cancer
FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Cervical Cancer
FDA Approves Mobocertinib for NSCLC with EGFR Exon 20 Insertion Mutations
FDA Grants Accelerated Approval to Zanubrutinib for R/R MZL
FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia
FDA Approves Updated Pembrolizumab Indication for UC
FDA Approves Companion Diagnostic for IDH1-Mutated Cholangiocarcinoma
New Permanent J-Code for Melphalan Flufenamide
FDA Approves Nivolumab for High-Risk Urothelial Carcinoma
FDA Approves Belzutifan for von Hippel-Lindau Disease-Associted Tumors
FDA Approves Levnatinib + Pembrolizumab for Advanced RCC
FDA Approves Pembrolizumab for High-Risk, Early-Stage TNBC
FDA Approves Pembrolizumab + Lenvatinib for Advanced Endometrial Cancer
CMS Releases Notice of Proposed Rulemaking for the RO Model
FDA Approves Belumosudil for Chronic GVHD
FDA Approves Daratumumab and Hyaluronidase-fihj in Combination for MM
FDA Approves Expanded Indication for Pembrolizumab for cSCC
FDA Approves FoundationOne® CDx as Companion Diagnostic for Brigatinib
FDA Approves Component of Chemotherapy Regimen for ALL and LBL
FDA Encourages Inclusion of Patients with Incurable Cancers in Clinical Trials
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
FDA Grants Accelerated Approval to Infigratinib for Cholangiocarcinoma
FDA Approves Guardant360® CDx Test for NSCLC with KRAS G12C Mutation
FDA Grants Accelerated Approval to Sotorasib for NSCLC
FDA Approves Companion Diagnostic for Amivantamab-vmjw
FDA Approves Amivantamab-vmjw for Subset of NSCLC
FDA Approves Nivolumab for Completely Resected Esophageal or GEJ Cancer
USPSTF Releases Updated Colorectal Cancer Screening Guidelines
FDA Approves Pembrolizumab in Combination for HER2-Positive Gastric Cancer
FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for R/R LBCL
